Osajin
CAS 482-53-1
Osajin (CAS 482-53-1) is a pharmaceutical compound with 6 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 24567.578666666665 nM | 66 | - |
| - | GI50 | 81198.57142857143 nM | 7 | - |
| - | IC50 | 15430.374285714284 nM | 6 | - |
| - | EC50 | 20011.4 nM | 5 | - |
| - | IC50 | 9.6 ug.mL-1 | 2 | - |
| - | Ki | 16555 nM | 2 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Osajin used for in pharmaceutical contexts?
Osajin (CAS 482-53-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Osajin?
No adverse-event association or SIDER side-effect rows are rendered for Osajin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Osajin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for OSAJIN with EU status "permitted".
What clinical phase is Osajin in?
No phase 1-4 clinical development badge is rendered for Osajin because the matched compound identifier rows do not contain a max-phase value.